Dosing & Uses
Dosage Forms & Strengths
tablet
- 150mg
- 500mg
Duke Stage C Colon Cancer
Adjuvant therapy
1,250 mg/m² PO BID x 2 weeks, followed by 1-week rest period, given as 3-week cycles for a total of 8 cycles (24 weeks)
Colorectal Cancer
Metastatic disease
1250 mg/m² BID for 2 weeks q21 days
Breast Cancer
Metastatic, resistant to paclitaxel, anthracyclines
Monotherapy: 1250 mg/m² BID for 2 weeks q3Weeks
Combo therapy with Docetaxel: 1250 m² PO BID for 2 weeks q3Weeks plus docetaxel 75 mg/m² 1 hour IV infusion q3Weeks
Administration
Swallow with water within 30 min after a meal
Dosage may need to be individualized to optimize patient management
Dose Modifications
Renal impairment
- CrCl 30-50 mL/min: Reduce dose by 25%
- CrCl <30 mL/min: Contraindicated
Safety & efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
Varies with carcinoma type
10%
Diarrhea
Nausea
Anemia
Lymphopenia
Hand and foot syndrome
Edema
Fatigue
Fever
Headache
Pain
Paresthesia
Alopecia
Dermatitis
Abdominal pain
Anorexia
Appetite decreased
Constipation
Dyspepsia
Stomatitis
Vomiting
Neutropenia
Thrombocytopenia
Dyspnea
Bilirubin increased
Eye irritation
1-10%
Chest pain
Dermatitis
Pruritus
Rash
Dizziness
Headache
Weakness
Dehydration
Dry mouth
Dyspepsia
Taste disturbance
Back pain
Postmarketing reports
Toxic leukoencephalopathy
Warnings
Black Box Warnings
Capecitabine may increase the anticoagulant effects of warfarin increasing the INR several days up to several months after initiating capecitabine or within one month after stopping the therapy. Risk factors include >60 years of age and cancer. Monitor closely
Contraindications
Hypersensitivity to capecitabine or fluorouracil (5-FU)
Severe renal impairment (CrCl <30 mL/min)
Cautions
May result in bleeding, death; monitor anticoagulant response (e.g., INR) and adjust anticoagulant dose accordingly
Diarrhea may be severe; interrupt capecitabine treatment immediately until diarrhea resolves or decreases to grade 1; recommend standard antidiarrheal treatments
May cause cardiomyopathy and acute decreases in LVEF
Increased risk of severe or fatal adverse reactions in patients with low or absent dihydropyrimidine dehydrogenase (DPD) activity; withhold or permanently discontinue capecitabine in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity; no capecitabine dose has been proven safe in patients with absent DPD activity
Interrupt capecitabine treatment until dehydration is corrected; potential risk of acute renal failure secondary to dehydration; monitor and correct dehydration
Can cause fetal harm; advise women of the potential risk to the fetus
Based on animal studies, therapy may impair fertility in females and males of reproductive potential
Severe mucocutaneous reactions, Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), reported; discontinue therapy in patients who experience a severe mucocutaneous reaction during treatment; capecitabine may induce hand-and-foot syndrome; interrupt capecitabine treatment until hand-and-foot syndrome event resolves or decreases in intensity; persistent or severe hand-and-foot syndrome can eventually lead to loss of fingerprints
If hypervilirubinemia occurs, interrupt therapy immediately until it resolves or decreases in intensity
Do not treat patients with neutrophil counts <1.5 x 10^9;/L or thrombocyte counts <100 x 10^9;/L; if grade 3-4 neutropenia or thrombocytopenia occurs, stop therapy until condition resolves
Contraception
- Advise females of reproductive potential to use effective contraception during treatment and for 6 months after last therapeutic dose
- Based on genetic toxicity findings, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after last therapeutic dose
Pregnancy & Lactation
Pregnancy
Based on findings in animal reproduction studies and its mechanism of action, therapy can cause fetal harm when administered to a pregnant; limited available human data are not sufficient to inform drug-associated risk during pregnancy
In animal reproduction studies, therapy in pregnant animals during period of organogenesis caused embryo lethality and teratogenicity in mice and embryo lethality in monkeys at 0.2 and 0.6 times, respectively, the exposure (AUC) in patients
Pregnancy testing is recommended for females of reproductive potential prior to initiating therapy
Lactation
There is no information regarding presence in human milk, or effects on milk production or breast-fed infant; drug metabolites were present in milk of lactating mice; because of potential for serious adverse reactions from exposure in breast-fed infants, advise women not to breastfeed during therapy and for 2 weeks after final dose
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Half-life: 0.75 hr
Peak Plasma Time: 1.5 hr
Protein Bound: <60%
Metabolism: hepatic
Metabolites: 5'-DFUR
Excretion: urine (95%)
Dialyzable: yes
Pharmacogenomics
Dihydropyrimidine dehydrogenase (DPD), an enzyme encoded by the DPYD gene, is the rate-limiting step in pyrimidine catabolism and deactivates >80% of 5FU standard doses and the 5FU prodrug capecitabine
Contraindicated in patients with DPD deficiency; causes severe toxicity with conventional doses (ie, grade III/IV toxicity and potentially fatal neutropenia, mucositis, and diarrhea)
Because true DPD deficiency is rare and because the clinical implications of partial deficiency are still unclear, screening for mutations prior to initiating therapy is not warranted
Genetic testing laboratories
- The following companies currently offer testing for DPYD*2A mutations
- EntroGen (http://www.entrogen.com)
- Myriad (http://www.myriadtests.com)
- LabCorp (http://www.labcorp.com)
- Molecular Diagnostics Laboratories (http://www.mdl-labs.com)
Mechanism of Action
Converted to 5-FU by thymidine phosphorylase in neoplastic tissue
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.